THEGL Inhibitors
Chemical inhibitors of THEGL can affect its function through various mechanisms by targeting specific pathways and enzymes that are crucial for its activity. Staurosporine, a potent protein kinase inhibitor, can inhibit THEGL by preventing its phosphorylation or the phosphorylation of its associated substrates, assuming that THEGL has kinase activity or is involved in phosphorylation processes. Similarly, LY294002 and Wortmannin, both PI3K inhibitors, can disrupt THEGL function if it is part of the PI3K/Akt pathway, which plays a significant role in cell survival and proliferation signals. Rapamycin, which inhibits mTOR, can affect THEGL's role in cell growth and metabolism if THEGL is involved in these processes through the mTOR signaling pathway.
Further, PD98059 and U0126, inhibitors of MEK1/2, can impede the function of THEGL by decreasing ERK activity or preventing its activation, respectively, if THEGL is a downstream component of the MAPK/ERK pathway that regulates cell division and differentiation. SB203580 and SP600125, targeting p38 MAPK and JNK respectively, can inhibit THEGL if it operates within the p38 MAPK stress response pathway or is linked to the JNK signaling pathway involved in stress responses, inflammation, and apoptosis. ZM-447439, an Aurora kinase inhibitor, can disrupt THEGL function by interfering with cell cycle progression signals if THEGL is involved in cell cycle regulation through interaction with Aurora kinases. Lastly, Imatinib, Sunitinib, and Dasatinib, which target various tyrosine kinases, can inhibit THEGL if its function is dependent on signaling pathways that involve these kinases, such as BCR-ABL signaling, VEGFR, PDGFR, or Src family kinases. These chemical inhibitors collectively demonstrate a range of mechanisms by which they can influence the function of THEGL, depending on its role within cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits protein kinases, and if THEGL has kinase activity or interacts with phosphorylation processes, staurosporine could hinder THEGL's functional role by preventing its phosphorylation or the phosphorylation of associated substrates. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3 kinase inhibitor. If THEGL is part of the PI3K/Akt pathway, LY294002 would inhibit this pathway, thereby inhibiting the function of THEGL related to cell survival and proliferation signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central protein in regulating cell growth and metabolism. Assuming THEGL is involved in these processes, rapamycin would inhibit the function of THEGL by disrupting the mTOR signaling pathway it may be associated with. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Inhibition of MEK would lead to decreased ERK activity, which would inhibit THEGL function if THEGL is part of the MAPK signaling cascade that regulates cell division and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If THEGL operates within the p38 MAPK stress response pathway, SB203580 would inhibit THEGL's function by blocking p38 MAPK-mediated signal transduction. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and if THEGL's function is linked to the JNK signaling pathway involved in stress responses, inflammation, and apoptosis, inhibition of JNK by SP600125 would accordingly inhibit THEGL's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and by inhibiting these kinases, U0126 would impede the activation of ERK1/2. If THEGL is a downstream effector in the ERK/MAPK pathway, then U0126 would inhibit THEGL's function by preventing its activation by ERK1/2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. If THEGL functions downstream of PI3K, Wortmannin would inhibit THEGL's function by blocking PI3K signaling which is crucial for many cellular functions including growth and survival. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor and if THEGL is involved in cell cycle regulation through interaction with Aurora kinases, ZM-447439 would inhibit THEGL function by disrupting cell cycle progression signals. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets BCR-ABL tyrosine kinase and if THEGL's function is dependent on BCR-ABL signaling for proliferation or survival, Imatinib would inhibit THEGL function by blocking this tyrosine kinase activity. | ||||||